drugset / Trial / NCT02344511

Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis

NCT02344511

RandomizedParallel-groupTriple-blindTreatment

Summary

Dalbavancin for Pediatric Osteomyelitis

Timeline

Start
2016-03
Primary completion
2018-10
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cefazolin Small molecule 25 mg/kg
Subject Dalbavancin Other / unclassified 10 mg/kg Intravenous
Subject Dalbavancin Other / unclassified 15 mg/kg Intravenous
Comparator Vancomycin Other / unclassified 15 mg/kg
Comparator nafcillin Small molecule 50 mg/kg
Comparator oxacillin Small molecule 50 mg/kg

Indications